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Abstract: Tetanus neurotoxin (TeNT) is one of the most poisonous substances on Earth 
and a major cause of neonatal death in non-vaccinated areas (1). TeNT targets the 
neuromuscular junction (NMJ) with high affinity, yet the nature of the TeNT receptor 
complex at the NMJ remains unknown (2). Here we show that nidogens (also known as 
entactins (3)) are highly enriched at the basement membrane of the NMJ and are essential 
for TeNT binding to motor neurons, where TeNT enters the central nervous system to exert 
its toxic effects. Inhibition of the TeNT-nidogen interaction using small nidogen-derived 
peptides or genetic ablation of nidogen-2 protects mice from TeNT-induced spastic 
paralysis. Our report is the first to demonstrate the direct involvement of a protein receptor 
for TeNT at the NMJ, paving the way for the development of novel therapeutics for the 
prevention of tetanus targeting this novel protein-protein interaction. 
Main Text:  
TeNT is formed by two subunits, which perform specific functions necessary for its 
toxicity. The heavy (H) chain mediates high-affinity binding and entry into neurons, 
whereas the light (L) chain causes synaptic silencing of inhibitory interneurons, which 
normally suppress motor neuron activity, thereby inducing spastic paralysis (4). After 
internalisation into motor neurons, the carboxy-terminal fragment of the H chain (HCT) is 
sorted to signalling endosomes, which undergo axonal retrograde transport towards the 
motor neuron cell body (5). We have previously characterised the proteome of these 
organelles using HCT-conjugated magnetic nanoparticles and mass spectrometry (5). This 
affinity isolation approach identified a list of proteins associated with signalling 
endosomes, some of which were predicted to be involved in the binding and/or 
internalisation of HCT. We analyzed the sequences of these proteins for the presence of the 
tripeptide Tyr-Glu-Trp (YEW), which was previously shown to interact with the sialic acid 
binding site of HCT (6) (R site), a region implicated in polysialogangliosides and acidic 
lipid binding (6, 7). In contrast, the corresponding region of BoNTs interacts with the 
synaptic proteins SV2A-C or synaptotagmin I/II (8-14), raising the possibility that this site 
of TeNT also binds to a protein receptor.  
We selected candidates containing variants of the YEW peptide within the lumen of 
signalling endosomes, a localization topologically equivalent to the extracellular domain of 
these proteins when localized to the plasma membrane (Supplementary Data Table 1). A 
total of 35 nine-residue peptides containing the YEW motif or closely related sequences 
were tested for binding to HCT using direct fluorescent binding, ELISA and in vitro pull 
down assays (Fig. 1A; Supplementary Fig. 1). The interacting peptides were then assessed 
for their ability to compete for HCT binding on primary neurons. Peptide N1, which 
corresponds to a short sequence in nidogen-1, a basement membrane (BM) protein 
(Supplementary Data Table 1; Supplementary Fig. 2A), was selected for further analyses as 
it significantly reduced HCT binding to motor neurons (Fig. 1C,D). The YEW-like motif of 
nidogen-1 (YQW) was responsible for this interaction since a mutant form of this peptide, 
in which the aromatic residues were replaced by alanines (AQA; N1AA) failed to inhibit 
HCT binding to motor neurons (Fig. 1C,D). 
We then tested whether HCT was capable of interacting directly with full-length 
nidogen-1. Incubation of immobilised HA-tagged HCT with full-length nidogen-1 revealed 
that the two proteins bind directly under these experimental conditions (Fig. 1B, upper 
panel). Moreover, the N1 peptide plays a key role in this interaction since pre-incubating 
HCT with an excess of this peptide, but not the N1AA mutant, abolishes this binding.  
Mammals express two nidogen isoforms that play partially redundant roles in BM 
formation and maintenance (15, 16). Whilst nidogen-2 knockout (KO) mice do not display 
any overt phenotype, animals lacking nidogen-1 develop a progressive hindlimb paralysis, 
indicating a role for this protein in motor neuron survival (17). Interestingly, nidogen-2 
contains a variant of the YEW peptide (WSY; N2; Supplementary Data Table 1), 
suggesting that both nidogen isoforms could bind HCT. Accordingly, we found that 
recombinant nidogen-2 directly binds to HCT and this interaction is blocked by the N2 
peptide, but not by its alanine mutant (ASA; N2AA)(Fig. 1B, lower panel and 
Supplementary Data Table 1). 
Nidogens are tightly integrated within the BM, which renders them hard to access 
for exogenous ligands. To determine whether nidogens are the limiting factor for HCT 
binding to motor neurons, we added soluble full-length nidogen-1 to cultured motor 
neurons together with HCT. This resulted in a dramatic increase in surface-bound HCT (Fig. 
1C,D), suggesting that the addition of exogenous nidogen-1 increases the number of HCT 
binding sites on the motor neuron surface. This effect is dependent upon the YEW-like 
motif of nidogen-1, since preincubation with the N1, but not the N1AA peptide prevents this 
effect (Fig. 1C,D). 
Inspection of the domain structure of nidogens revealed that N1 and N2 peptides are 
present in the globular G2 domain (Supplementary Fig. 2A). Molecular modelling 
(Supplementary Fig. 2B-D) reveals that the N1 peptide, both in isolation and within the 
intact G2 domain, is able to dock to the R site of HCT, where sialic acid, disialyllactose and 
the tri-peptide YEW, bind (6). Surprisingly, the molecular surface concealed by the N1 
peptide-HCT complex constitutes more than 40% of the total peptide surface 
(Supplementary Fig. 2C), suggesting that the binding, which is driven by the potential 
formation of five hydrogen bonds and other polar interactions (Supplementary Data Table 
2), is very strong. 
The G2 domain of nidogen-1 fits into a large crevice at the top of the trefoil domain 
of HCT (Supplementary Fig. 2B), concealing 1,114 Å2 and 1,106 Å2 for HCT and the G2 
domain of nidogen-1, respectively. Complex formation is likely to be promoted by 
complementary electrostatic surfaces and several potential hydrogen bonds (Supplementary 
Data Table 3 and Supplementary Fig. 2D). Crucially, the association between HCT and 
nidogen-1 is unlikely to interfere with the interaction between HCT and 
polysialogangliosides, which is required for TeNT binding to the neuronal surface (7, 18). 
Thus, nidogens and polysialogangliosides have the potential to bind TeNT simultaneously, 
and thereby fulfil the requirements for the proposed dual receptor model (19, 20), which 
predicts the concurrent interaction of lipid and protein receptors to TeNT and BoNTs for 
their high-affinity binding to neuronal membranes. 
To determine whether HCT and nidogens co-localize at the specialised BM forming 
the synaptic cleft of the NMJ, we incubated freshly dissected levator auris longus (LAL) 
muscle firstly with HCT, followed by an antibody against nidogen-2 (α-nidogen-2). Both 
nidogen-2 and HCT displayed similar distributions at the NMJ, which closely resembled the 
staining pattern obtained with α-bungarotoxin (BTX), a presynaptic NMJ marker, 
suggesting that both nidogen-2 and HCT accumulate at the synaptic cleft (Fig. 2A). We then 
asked whether these two proteins are internalised and transported together in signalling 
endosomes. HCT and α-nidogen-2 were added to motor neurons at 37˚C and after a mild 
acid wash to remove all probes still bound to the neuronal surface, we immunostained for 
α-nidogen-2. The extensive co-localization between α-nidogen-2 and HCT along the axon 
strongly indicated that these two proteins were internalised and transported by the same 
organelles (Fig. 2B). Furthermore, co-immunoprecipitation of HCT and endogenous 
nidogen-2 from motor neurons incubated with HCT for 5 minutes at 37˚C (Fig. 2C) 
suggested that this interaction is preserved upon entry of HCT into endosomal 
compartments. 
After axonal transport to the cell body, TeNT undergoes transcytosis and re-uptake 
into spinal interneurons, where it blocks the release of inhibitory neurotransmitters, leading 
to the characteristic symptoms of clinical tetanus (4). To address whether nidogens are 
targeted together with HCT to the plasma membrane of soma and dendrites following 
axonal transport, motor neurons were plated into microfluidic chambers (21) and co-
incubated with fluorescent HCT and α-nidogen-2 in the axonal compartment (AX; 
Supplementary Fig. 3A) for 2 h at 37˚C. The somal side (CB; Supplementary Fig. 3A) of 
these chambers was then immunostained in non-permeabilizing conditions to determine 
whether HCT and nidogen-2 were subsequently re-exposed onto the plasma membrane. 
This was indeed the case, as shown by the co-localization of the two probes as distinct 
punctae on the motor neuron surface (Supplementary Fig. 3B). This observation suggests 
that the nidogen-HCT complex persists all along the intracellular trafficking route 
connecting the NMJ to the spinal cord and may facilitate the transcytosis of TeNT into 
inhibitory interneurons (4), thus clarifying the mechanism by which TeNT targets these 
neurons to exert its toxic function.  
To further test the importance of nidogens in TeNT intoxication, we assessed the 
ability of HCT to bind nidogen KO neurons and tissue, and determined the susceptibility of 
nidogen KO mice to TeNT-induced paralysis. We observed a significant decrease in the 
amount of HCT bound to nidogen-2 KO motor neurons compared to wild type neurons (Fig. 
3A,B). Next, we tested whether the NMJ uptake of HCT was impaired in mice lacking 
nidogens. For this purpose, isolated LAL muscles were incubated with HA-HCT and 
immunostained for HA, which revealed a dramatic reduction in the ability of NMJs from 
both nidogen-1 and nidogen-2 KO mice to bind and internalise HCT (Fig. 3C,D). Nidogen-
1 and -2 double knockout (DKO) animals show early embryonic lethality (22), precluding 
the derivation of motor neuron cultures from these mice. To overcome this limitation, we 
assayed HCT uptake in hindbrains of DKO embryos at E11.5. Whilst control hindbrains 
displayed robust HCT staining (Fig. 3E, left), hindbrains from DKO littermates were unable 
to bind HCT, indicating that nidogen-1 and -2 are essential for HCT binding in vivo (Fig. 
3E,F). 
Having identified nidogens as novel HCT co-receptors, we next investigated the 
ability of the N1 peptide to prevent uptake of TeNT in vivo, using three independent assays. 
Firstly, full length TeNT was injected locally into the triceps surae muscle either alone, or 
in combination with N1 or N1AA and the effect on spastic paralysis was assessed using 
footprint analysis 24 h after injection (Fig. 4A,B). TeNT caused a permanent plantar-
flexion of the affected hind-paw (Supplementary Movie 1) and severe gait abnormalities, 
with the characteristic inability to place the affected hind-paw in the former position of the 
ipsilateral fore-paw, as occurs in normal mice (Fig. 4A,B). Strikingly, co-administration of 
the N1 peptide completely abolished these TeNT-induced gait abnormalities 
(Supplementary Movie 1), whereas the N1AA peptide was ineffective (Fig. 4A,B).  
To corroborate this finding, we quantified the protective effect of the N1 peptide co-
injected with TeNT on the TeNT-induced spastic paralysis by measuring the maximal force 
generated by the tibialis anterior muscle using isometric muscle tension physiology. The 
contractile force of the TeNT-injected muscle was diminished (3.11±0.88% of non-injected 
control)(Fig. 4C, Supplementary Fig. 4A), as was the case with muscles co-injected with 
TeNT and the N1AA peptide (2.14±1.44% of non-injected control)(Fig. 4C, Supplementary 
Fig. 4B). Co-administration of the N1 peptide reduced the TeNT-mediated decline in 
contractile force compared to the other two groups (47.46 ±10.31% of non-injected 
control)(Fig. 4C, Supplementary Fig. 4C). Similar results were obtained using phrenic 
nerve-hemidiaphragm preparations (23) (Supplementary Fig. 4D). Together, these results 
confirm the ability of the N1 peptide to prevent symptoms of tetanus in vivo. 
Next, we injected wild type and nidogen-2 KO mice intraperitoneally with different 
doses of TeNT and closely monitored the appearance of the hallmark symptoms of tetanus. 
Nidogen-2 KO animals showed a significant delay in the onset and progression of tetanic 
symptoms at lower TeNT doses (Fig. 4D). Unfortunately, the possibility to extend these 
assays to mice lacking nidogen-1 was precluded by the severe epileptic and paralytic 
phenotype affecting these animals (17). 
Interestingly, some of the symptoms observed in nidogen-2 KO mice injected with 
TeNT, such as keratoconjuctivitis sicca (24) (data not shown), resembled those of botulism, 
suggesting that in the absence of one of its physiological receptors, a proportion of TeNT 
may exploit an alternative route of entry at the NMJ, which is shared with BoNTs. Cross 
talk between the two modes of entry and intracellular transport pathways of TeNT and 
BoNT has been previously suggested (21), and is supported by the botulism-like symptoms 
shown by mice injected with high doses of TeNT (25).  
Since BoNTs use several SV2 isoforms as receptors (12-14, 23) and SV2A has been 
proposed as TeNT receptor in inhibitory neurons (26), we quantified the co-localization of 
HCT with SV2A and C in motor neurons and tested if pre-incubation of HCT with 
recombinant nidogen-1 altered this process. SV2A showed robust co-localization with HCT 
internalised for 45 min at 37 °C (45%; Fig. 4E,F), whereas the co-distribution of HCT with 
SV2C was negligible (Supplementary Fig. 4C,D). This result suggests that at least a sub-
pool of TeNT could be internalised via synaptic vesicle recycling at the relatively high 
concentrations of HCT used in our binding assay (40 nM). However, the addition of 
recombinant nidogen-1 caused a significant reduction in the co-localization between HCT 
and SV2A (Fig. 4E,F) but not SV2C (Supplementary Fig. 4E,F). This decrease is due to the 
dramatic increase of the pool of HCT accumulated in the soma (Fig. 4E), suggesting that in 
the presence of exogenous nidogens, HCT is preferentially targeted to an endocytic pathway 
linked to axonal retrograde transport and avoids the synaptic vesicle recycling route.  
In conclusion, we have identified the long-awaited protein receptor for TeNT at the 
NMJ as well as a potential mechanism to explain the overlap between the entry routes of 
TeNT and BoNT (Supplementary Fig. 5). Interestingly, engineered growth factors with 
higher affinity for the extracellular matrix display enhanced biological activity (27), 
indicating that this process is crucial for their signalling and biological function (28). TeNT 
might exploit a similar strategy based on a very efficient capture mechanism at specialised 
NMJ sites, which could concentrate TeNT as well as physiological ligands, such as 
neurotrophic factors, for their uptake and sorting to transport organelles. This physiological 
pathway is likely to be indispensable to the host cell, enabling TeNT to be so deadly at such 
low concentrations. Understanding this mechanism at a molecular level is therefore crucial 
to refine the biological properties of bioactive peptides for their use in human therapy, and 
to develop specific molecules altering the capture of this powerful toxin at the NMJ, thus 
blocking its CNS effects. 
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Figures 
 
Fig. 1. Nidogen peptides bind to HCT and prevent its interaction with full-length 
nidogens in vitro. (A) In vitro screen for peptides that bind fluorescent HCT. The 
percentage of maximal binding was plotted for each peptide. The results were analyzed 
with paired t test between the individual peptides and Tris-buffered saline (TBS) controls 
(n=3; *, p<0.05; error bar: SD). (B) In vitro pull down of HA-HCT preincubated with full 
length nidogen-1 (upper panel) or nidogen-2 (lower panel) with a mouse monoclonal anti-
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HA antibody followed by SDS-PAGE and western blotting with rabbit anti-nidogen-1, 
rabbit anti-nidogen-2 or rat anti-HA antibodies. ‘Empty beads’ corresponds to samples in 
which HA-HCT was omitted, and DMSO to samples treated with vehicle control. Both 
nidogen-1 and -2 bind directly to HA-HCT, and pre-treatment with the N1 or N2 peptide 
blocks this interaction. In contrast, mutant peptides in which both the Y and W residues 
have been replaced by alanines (N1AA and N2AA, respectively) are ineffective (n=3 for both 
proteins). (C) Motor neurons were incubated with AlexaFluor555-HCT preincubated with 
vehicle control (HCT alone) or wild type and mutant versions of the N1 peptide in the 
absence or the presence of exogenous nidogen-1 before staining for βIII tubulin and 
confocal imaging. Scale bar, 50 µm. (D) Twenty images were taken for each condition and 
fluorescence intensity of AlexaFluor555-HCT bound to neurons (βIII tubulin mask) was 
quantified. Results were tested for statistical significance using one-way ANOVA followed 
by Dunnett’s Multiple Comparison Test (n=3; NS, non significant; ***, p<0.005; ****, 
p<0.001; error bar: SD).  
 
Fig. 2. Nidogen-2 co-localizes with HCT at the neuromuscular junction and in primary 
motor neurons. (A) Whole mounts of levator auris longus (LAL) muscle were incubated 
with HA-HCT and an antibody against nidogen-2. Neuromuscular junctions (NMJs) were 
labelled with AlexaFluor555-α-bungarotoxin (BTX, in green). HCT (in red) binds to the 
NMJ at sites where nidogen-2 accumulates (grey). Scale bar, 5 µm, n=3. (B) Primary motor 
neurons were incubated with AlexaFluor555-HCT and a rabbit anti-nidogen-2 antibody. 
Cells were acid washed, fixed and stained with an anti-rabbit IgG antibody. Scale bar, 5 µm 
(n=3). (C) Primary motor neurons were incubated with HA-HCT for 5 min at 37˚C to allow 
binding and endocytosis. Since the binding of HCT is detergent-sensitive, to preserve these 
interactions cells were pre-treated with a protein cross-linker (BSOCOES) before cell lysis. 
Nidogen-2 was immunoprecipitated from motor neuron lysates using an anti-HA antibody. 
In control samples, HA-HCT was omitted (n=3). 
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 Fig. 3. Neurons lacking nidogens display reduced binding to HCT. (A) Motor neurons 
derived from E13.5 wild type and nidogen-2 knockout (KO) embryos were incubated with 
AlexaFluor555-HCT (grey). Cells were fixed and fluorescence intensity was measured in 10 
images using a βIII tubulin mask (in green). (B) Results were plotted and analyzed using an 
unpaired t test with Welch’s correction (n=3; ***, p<0.005; error bar: SD). (C) Levator 
auris longus (LAL) muscles of wild type, nidogen-1 and -2 KO animals were incubated 
with HA-HCT, fixed and stained for HA (grey) and AlexaFluor555-α-bungarotoxin (BTX, 
in green) to identify neuromuscular junctions (NMJs). (D) Both nidogen-1 and -2 KO 
NMJs show a significant decrease in their ability to bind and internalise HCT (one-way 
ANOVA followed by Dunnett’s Multiple Comparison Test; n=3 animals per group, 20 
images per animal; ***, p<0.005; error bar: SD). (E) Nidogen-1 and -2 double KO (DKO) 
and wild type E11.5 embryonic hindbrains were tested for HCT binding and uptake. (F) 
Mean intensity of HCT staining was measured and analyzed for significance using unpaired 
t test (n=3 animals per group; **, p<0.01; error bar: SD).  
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Fig. 4. The N1 peptide blocks tetanic paralysis and mice lacking nidogen-2 are less 
sensitive to TeNT. (A) Footprint analysis of control mice, or mice following injection into 
the gastrocnemius muscle of a sub-lethal dose of TeNT, or the same amount of TeNT 
preincubated with the N1AA or N1 peptides. The black circles show the non-injected paw 
prints; while the red circles mark the right hind paw (injected leg) prints. In control and 
TeNT+N1 mice, the black and red circles overlap, whilst in TeNT and TeNT+N1AA mice 
they are separated, indicating impairment in coordination due to local tetanus. (B) The 
distance between the paw prints on the injected side was measured and plotted to allow 
testing for statistical significance using one-way ANOVA followed by Dunnett’s Multiple 
Comparison Test (n=2, 2 animals per group; NS, non significant; **, p<0.01; ****, 
p<0.001; error bar: SD). (C) The tibialis anterior (TA) muscle was injected with TeNT 
preincubated with either DMSO (vehicle control), N1AA or N1 peptides. Following 
anaesthesia, the tendon of the TA muscle was attached to a tension sensor and the peroneal 
nerve was stimulated. Maximal muscle force was measured, normalized to muscle weight 
and tested for significance (control vs. injected muscle). The N1-treated group retained a 
significantly higher muscle force than the vehicle- or N1AA-treated groups. Significance 
was assessed by unpaired t test with Welch’s correction (n=6 mice per group; **, p<0.01; 
error bar: SD). (D) Age and weight matched nidogen-2 KO and wild type mice were 
injected intraperitoneally with increasing doses of TeNT and monitored for up to 96 h. 
Animals were terminated at the loss of righting reflex and the time of termination was 
plotted against the dose of TeNT. Generalised tetanus in nidogen-2 KO animals is 
significantly delayed at lower doses (2 ng/kg) compared to wild type controls (n=2 
experiments, minimum 2 mice per group; t test; ***, p<0.005; error bar: SD). (E) Wild type 
primary motor neurons were incubated either with AlexaFluor555-HCT (shown in red; 40 
nM) alone, or with AlexaFluor555-HCT and recombinant full-length nidogen-1 (1.3 nM). 
Cells were fixed and stained for SV2A (in green) and βIII tubulin (not shown). (F) 
Mander’s coefficient was used as an indicator of co-localization. Significance was assessed 
by unpaired t test (n=3, 10 images per condition; NS, non significant; ***, p<0.005; error 
bar: SD). Scale bar, 10 µm. 
Supplementary Materials: 
Materials and Methods:  
Ethics statement 
All experiments were carried out following the guidelines of the Cancer Research 
UK and UCL-Institute of Neurology genetic manipulation and Ethic Committees and in 
accordance with the European Community Council Directive of November 24, 1986 
(86/609/EEC). Animal work was carried out under licence from the UK Home Office in 
accordance with the Animals (Scientific Procedures) Act 1986. 
Reagents 
All reagents were obtained from Sigma, unless stated otherwise. AlexaFluor-
maleimide and AlexaFluor-conjugated antibodies were purchased from Life Technologies. 
Recombinant nidogens were purchased from R&D Systems. HCT (441 residues) with an 
improved cysteine-rich tag was prepared as previously described (29) and labelled with 
AlexaFluor555-maleimide following manufacturer’s instructions, prior to dialysis against 
HEPES-NaOH 10 mM pH 7.4, 150 mM NaCl. 
In vitro binding assays 
To screen peptides for HCT binding, we dried 10 ng of biotin-labelled peptides on a 
96-well plate overnight and incubated with Tris-buffered saline (TBS) containing 0.05% 
Tween and 1% bovine serum albumin (BSA) for 1 h to block unspecific interactions. Plates 
were then washed with TBS containing 0.05% Tween (TBST) three times before adding 40 
nM AlexaFluor555-HCT in TBS and incubating it overnight at 4°C. Plates were then 
extensively washed with TBS and the fluorescent signal was measured using an EnVision® 
Multilabel Plate Reader.  
For classic ELISA, 96-well plates were prepared as before, washed with TBST three 
times before adding 4 nM VSVG-HCT in TBS and then incubated overnight at 4°C. Wells 
were extensively washed with TBS and incubated with a monoclonal mouse antibody 
against VSVG (clone P5D4, Cancer Research UK; 1:500 in TBST) for 2 h at room 
temperature. Following washes with TBST, an HRP conjugated goat anti-mouse secondary 
antibody (1:2,000) was added for 1 h at room temperature. Wells were then washed with 
TBST and blocked with TBST+1% BSA before adding ortho-phenylenediamine (OPD) for 
20 min. The reaction was stopped with 2 M HCl and absorbance at 490 nm was measured. 
Results were analyzed using unpaired t test. 
For the in vitro immunoprecipitation assay, the biotin-tagged peptides (20 nM) were 
bound to streptavidine-coated agarose beads, and used to test the binding between the 
peptides and VSVG-HCT. We added 1 mg VSVG-HCT to the beads, and after extensive 
washes in TBS, samples were treated with Laemmli sample buffer, analyzed by SDS-
PAGE and western blotting using the P5D4 anti-mouse monoclonal antibody. The intensity 
of the bands was measured in Image J and the results were analyzed by paired t test 
comparing the peptide bound beads to the empty bead control.  
For the in vitro pull down assay, we bound HA-HCT (1 mg) to α-HA (2 mg) coupled 
magnetic Dynabeads® (10 ml; Life Technologies). After blocking with 0.1 mg/ml BSA in 
phosphate buffered saline (PBS) for 1 h, samples were incubated with peptides (24 µM) or 
DMSO for 1 h at room temperature, washed and recombinant nidogens (0.5 mg of nidogen-
1 or 1 mg of nidogen-2) were added to bind overnight at 4°C. Beads were then washed with 
PBS and bound proteins solubilised using Laemmli sample buffer prior to SDS-PAGE and 
immunoblotting using rabbit anti nidogen-1 and nidogen-2 (Abcam, ab14511 and ab14513 
respectively; 1:500) and rat anti HA (3F10, Roche; 1:1000) antibodies. 
For the cell-based endogenous immunoprecipitation, HA-HCT (80 nM) was added 
to primary motor neurons for 5 min at 37 °C to allow endocytosis. The cells were 
immediately cooled on ice, washed with ice-cold Hank’s buffer and proteins were cross-
linked using BSOCOES (1 mM; Thermo Scientific) in PBS for 30 min at 4°C. The reaction 
was stopped by the addition of 50 mM Tris-HCl pH 7.5 (final concentration). Following 
washes with PBS, cells were lysed on ice using IP lysis buffer (20 mM Tris-HCl, 137 mM 
NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP40, HALT protease inhibitors (Thermo 
Scientific)). The lysates were cleared by centrifugation and proteins binding to empty beads 
were cleared by incubating the samples with empty Dynabeads for 30 min at room 
temperature. Monoclonal mouse anti-HA antibody (12CA5; Cancer Research UK; 2 µg) 
was cross-linked to Dynabeads (20 µl; Invitrogen) using BS3 (Thermo Scientific, 5 mM in 
20 mM sodium phosphate, 150 mM NaCl, pH 8) rotating for 30 min at room temperature 
and quenched by addition of 50 mM Tris-HCl pH 7.5 rotating for 15 min at room 
temperature. Beads were then incubated with lysates on a rotating wheel for 2 h at 4°C, 
magnetically isolated, washed and analyzed by SDS-PAGE and immunoblotting using 
rabbit anti nidogen-2 (Abcam, ab14513; 1:500) and rat anti HA (3F10, Roche; 1:1000) 
antibodies. 
Molecular modelling of the nidogen-1/N1 peptide-HCT interaction 
The crystal structure of HCT with the tri-peptide YEW bound (PDB ID 1YXW)(6) 
was used as a template. The N1 peptide (THIYQWRQT) was built using software Coot 
(30) replacing the glutamic acid with a glutamine within the YEW peptide; the remaining 
residues (THI---RQT) were manually built and adjusted inside the crevice of HCT. The 
structure was optimized by several runs of energy minimisation with the CNS software 
(31). 
A model of the human nidogen-1 fragment (amino acids 389 to 661), was built by 
homology modeling using the Swiss-Model web server (32) based on the crystal structure 
of mouse nidogen-1 G2/perlecan Ig3 complex as a template (PDB code 1GL4) (33). There 
is 85% sequence identity between the human and mouse proteins.  
The peptide 604-612 of human nidogen-1 was manually superimposed to N1 
peptide in the nidogen-1-HCT complex using Coot. The model of the two proteins was 
optimized by energy minimisation and subjected to molecular dynamics with software 
CNS. Several steps of dynamics at room temperature were performed, keeping the structure 
of nidogen-1 fixed. The Cα atoms of HCT were harmonically restrained during the 
dynamics, with the exception of residues 1142-1149 and 1212-1227 in the interaction 
region of the two proteins, which were left free to move. 
Immunofluorescence assays on primary motor neurons 
Spinal cord motor neurons were prepared from E13.5 old mouse embryos (C57/Bl6, 
Charles River) and plated onto poly-L-ornithine and laminin coated glass coverslips, or 
microfluidic chambers (21). For HCT binding studies, wild type motor neurons were cooled 
on ice prior to incubation with HCT (20 nM), which was pre-treated with either DMSO, or 
the N1/N1AA peptide (20 µM), or recombinant nidogens (1 nM), or a combination of the 
above for 1 h at room temperature at a molar ratio of 1:20:20,000 (recombinant nidogen-
1:HCT:N1/N1AA peptide). Cells were incubated with fluorescent HCT for 10 min before 
washing with ice-cold Hanks’ buffer (20 nM HEPES-NaOH pH 7.4, 0.44 mM KH2PO4 
0.42 mM NaH2PO4, 5.36 mM KCl, 136 mM NaCl, 0.81 mM MgSO4, 1.26 mM CaCl2, 6.1 
mM glucose) and fixing with 4% paraformaldehyde (PFA) in PBS for 15 min at room 
temperature. To obtain a mask for fluorescence intensity quantification, we stained the cells 
with a mouse monoclonal antibody against βIII tubulin (Covance, MMS-435P; 1:1,000) 
and an AlexaFluor488-conjugated goat anti-mouse secondary antibody (1:500). Twenty 
images were acquired for each condition using a Zeiss LSM510 confocal microscope 
equipped with a Zeiss 40x objective and analyzed for HCT binding using Cell Profiler. The 
mean fluorescence intensity was plotted for each condition and statistical significance was 
analyzed using one-way ANOVA followed by Dunnett’s multiple comparison test. 
For assessing the ability of nidogen-2 KO primary motor neurons to bind HCT, we 
isolated motor neurons from nidogen-2 KO and wild type embryos and cultured them for 7-
10 days (DIV 7-10). Cells were cooled on ice, and incubated with HCT (20 nM) for 10 min. 
Following a wash with ice-cold Hanks’ buffer, the cells were fixed with 4% PFA in PBS 
for 15 min at room temperature). We stained the coverslips with mouse monoclonal 
antibody against βIII tubulin (Covance, MMS-435P; 1:1,000) and an AlexaFluor488-
conjugated goat anti-mouse secondary antibody (1:500). Ten images were acquired for each 
condition using a Zeiss LSM510 confocal microscope equipped with a Zeiss 40x objective 
and analyzed for HCT binding using Cell Profiler. The mean fluorescence intensity was 
plotted for each genotype and statistical significance was analyzed using unpaired t test 
with Welch’s correction. 
For co-localization studies, motor neurons were incubated with fluorescent HCT (40 
nM) together with rabbit polyclonal antibody against nidogen-2 (Abcam, ab14513; 1:500) 
at 37°C for 45 min, then cooled on ice and subjected to an acid wash (2 min; 100 mM 
citrate-NaOH, 140 mM NaCl, pH 2.0) to remove the surface bound probes before fixation 
with 4% PFA in PBS for 15 min at room temperature. Cells were permeabilized using 0.1% 
Triton X100 in PBS for 10 min at room temperature and blocked with 5% BSA in PBS for 
1 h. The primary antibody was revealed using an AlexaFluor647 goat-anti-rabbit secondary 
antibody. 
For the SV2 co-localization studies, motor neurons were incubated either with 
fluorescent HCT alone (40 nM), or together with recombinant nidogen-1 (1.6 nM; R&D 
Systems; 2570-ND-050) for 45 min at 37 °C. Cells were then acid washed, fixed, 
permeabilized and blocked as described above prior to staining with a rabbit polyclonal 
antibody against SV2A (Synaptic System; SYSY119002; 1:500) or SV2C (a kind gift by T. 
Südhof; 1:100) and a mouse monoclonal antibody against βIII tubulin. Primary antibodies 
were detected as described above.  
Samples were imaged as before using a Zeiss 63x, Plan Apochromat oil-immersion 
objective. The Zeiss LSM510 confocal microscope was optimized for co-localization 
analysis and the pinholes were adjusted to match each other in every channel. The sampling 
was set to maximum and the level of co-localization was quantified using ImageJ. We 
determined Mander’s coefficient on randomly chosen fields and statistical significance was 
assessed using unpaired t test with Welch’s correction. 
For transcytosis assays, we designed microfluidic chambers with short 
microgrooves (500 µm). Chambers were hydrated with 0.8% BSA in PBS overnight at 
37°C before coating with poly-L-ornithine and laminin (21). Primary motor neurons were 
plated in the somatic side (CB; Supplementary Fig. 3a) and left to adhere before adding 
filling the chamber with complete motor neuron medium. Experiments were performed 
between DIV7-10 after the neurons have extended their axons to the other side of the 
chamber.  
To test whether nidogen-2 was re-exposed together with HCT on the surface of 
motor neurons after axonal retrograde transport, we added AlexaFluor555-HA-HCT (40 
nM) together with a rabbit polyclonal antibody against nidogen-2 (Abcam; ab14513; 1:500) 
to the axonal side (AX; Supplementary Fig. 3a) of the device and incubated for 2 h at 37°C. 
Cells were then fixed with 4% PFA in PBS, blocked with 5% BSA in PBS and stained with 
a monoclonal anti-HA antibody (Roche; 3F10; 1:500) in detergent-free conditions. Samples 
were washed and stained with goat anti-rabbit (AlexaFluor647; 1:500) and anti-mouse 
(AlexaFluor488) secondary antibodies (1:500) to reveal the transcytosed pool of HCT and 
nidogen-2, respectively. 
Hemidiaphragm and muscle tissue preparation 
Mouse phrenic nerve-hemidiaphragms were dissociated from male Swiss-Webster 
CD1 mice weighting about 20 g and mounted in 2-4 ml of oxygenated (95% O2, 5% CO2) 
Krebs-Ringer solution of the following composition: 137 mM NaCl, 5 mM KCl, 1.8 mM 
CaCl2, 1.0 mM MgCl2, 24 mM NaHCO3, 1 mM NaH2PO4 and 11 mM glucose, pH 7.4, at 
37°C. Two innervated hemidiaphragm preparations were isolated from each animal; 
muscles were stretched to the optimal length for twitch response and allowed to equilibrate 
for at least 20 min at 37°C before the start of the experiment. The phrenic nerve was 
stimulated via two ring platinum electrodes with supramaximal stimuli of 10 V amplitude 
and 0.1 ms pulse duration with a frequency of 0.1 Hz. Muscle contraction was monitored 
with an isometric transducer (Harvard Apparatus); data was recorded and analyzed via an i-
WORX 118 system with Labscribe software (Harvard Apparatus). TeNT aliquots (final 
concentration 5 nM) were preincubated with vehicle (DMSO) or with the N1 peptide (2.5 
µM), corresponding to a molar ratio of 1:500 (TeNT:peptide), for 1 h at room temperature, 
and then added directly to tissue bath of two nerve-muscle preparations obtained from a 
single animal.  Muscular twitch was monitored until complete paralysis. Data are expressed 
as time required to decrease the twitch to 50% of the initial value (paralysis half-time). 
To determine whether nidogen-2 and HCT co-localize at the NMJ, we isolated 
levator auris longus (LAL) muscles from wild type mice and incubated them with HCT (40 
nM) and the rabbit antibody against nidogen-2 (1:500) in motor neuron medium. The 
muscle was then fixed in 10% neutral buffered formalin (NBF) overnight at 4°C, then 
permeabilized and blocked using 1% BSA and 0.1% Triton-X100 in PBS for 2 h at room 
temperature. A rat anti-HA antibody (3F10, Roche; 1:1,000) was added to the sample. 
Following washing with PBS, samples were stained with goat secondary antibodies against 
rabbit (AlexaFluor647) and rat (AlexaFluor488) IgG (1:500), and with AlexaFluor555-
αBTX (1:1,000), mounted with Mowiol and imaged using a Zeiss LSM780 confocal 
microscope equipped with a Zeiss 40x Plan Apochromat oil-immersion objective. 
We isolated LAL muscles from nidogen-2 KO mice to assess their ability to 
accumulate HCT at the NMJ. The muscles were incubated with HCT (20 nM) in motor 
neuron medium for 2 h at 37 °C, fixed in 10% NBF overnight at 4°C then subjected to the 
same immunofluorescence protocol as before. We used AlexaFluor555-BTX (1:1,000) and 
goat α-rat AlexaFluor488-IgG (1:500), to identify the NMJs and assess HCT binding. The 
muscles were mounted with Mowiol and imaged using a Zeiss LSM780 confocal 
microscope equipped with a Zeiss 40x Plan Apochromat oil-immersion objective. We used 
BTX staining as a mask and analyzed HCT binding by measuring the mean fluorescence 
intensity of the green channel in Cell Profiler. The results were plotted and tested for 
significance by one-way ANOVA followed by Dunnett’s multiple comparison test.  
We dissected hindbrains of nidogen-1 and -2 KO (DKO) embryos at E11.5 to 
determine whether the complete loss of nidogens affects HCT binding. The hindbrain 
preparations were incubated with HCT in motor neuron medium for 2 h at 37 °C, followed 
by 10% NBF fixation overnight at 4°C. The samples were immunostained using the same 
protocol as for the nidogen-2 KO motor neurons. The hindbrains were mounted with 
Mowiol and imaged using a Zeiss LSM780 confocal microscope equipped with a Zeiss 20x 
Plan Apochromat objective. The mean grey value of the red channel was determined within 
the boundaries of the hindbrain in Image J, plotted and tested for significance using 
unpaired t test. 
Footprint and gait analysis 
Age and body mass matched C57/Bl6 male mice were injected with TeNT (1 or 2 
ng/kg) preincubated with either DMSO, the N1 or the N1AA peptide at a molar ratio of 1: 
13,800 (TeNT:peptide) for 1 h at room temperature at two different doses in the right 
triceps surae muscle. Mice were monitored for period of 96 h unless they reached the 
humane endpoint (appearance of moderate symptoms: hunched back and paralysis of rear 
limbs, or disappearance of the righting reflex for 30 s) earlier. We performed a footprint 
assay as previously described (34). To quantify the extent of paralysis, we measured the 
distance between the contralateral (injected side) front and hind paw prints. This parameter 
provides a reliable assessment of normal foot positioning during walking in mice, whereas 
triceps surae paralysis results in an increased distance between. Data were analyzed using 
one-way ANOVA followed by Dunnett’s multiple comparison test to compare the groups. 
Following termination, triceps surae muscles were dissected and weighed to determine 
whether the administered dose based on total body weight was in accordance with the 
dose/mg muscle.  
Isometric muscle tension physiology 
8-week old female C57Bl6 mice received unilateral intramuscular injection into the 
tibialis anterior (TA) muscle of TeNT (0.125 ng/kg, 4 µl total volume per 20 g body mass), 
after preincubation with vehicle (DMSO), N1 or N1AA peptides at a molar ratio of 1: 13,800 
(TeNT:peptide) for 1 h at room temperature. After 24 h, under terminal anaesthesia, 
isometric muscle tension force was recorded from the distal TA tendon following electrical 
stimulation (40-100 Hz, 0.02 ms square-wave pulses, for 450 ms) of the exposed sciatic 
nerve to induce maximal tetanic muscle contraction, as previously described (35). 
Contractile force of injected muscles was compared to contralateral (non-injected) TA 
muscle, as an internal control, and average changes within each group were analyzed using 
unpaired t test. 
Analysis of TeNT toxicity in nidogen-2 KO mice 
Age and body mass-matched wild type and nidogen-2 KO mice were injected 
intraperitoneally with different doses of TeNT (1.5, 3, 6, 12 ng/kg). Mice were monitored 
for up to 96 h. The experiment was terminated when mice showed moderate symptoms 
(hunched back and paralysis of rear limbs or disappearance of the righting reflex for 30 s). 
The time of survival prior to termination was plotted against the administered dose of 
TeNT. The groups were analyzed using paired t test for each dose.  
  
Supplementary Tables and Figures 
 
Peptide Gene name Sequence 
A Coxsackievirus and adenovirus receptor homolog PLQFEWQKL 
B Glypican-4 DLDFEWNNF 
C Neural cell adhesion molecule 1 VAVYTWEGN 
D Nicastrin SRSFFWNVA 
DA Nicastrin SRSFFANVA 
DAA Nicastrin SRSAFANVA 
D2 Nicastrin SRSFFWNVA 
D3 Nicastrin LYEYSWVQG 
E Poliovirus receptor-related protein 2/Nectin-2 PTDYDWSTT 
E2 Poliovirus receptor-related protein 2/Nectin-3 PTDAAASTT 
F Msn KIGFPWSEI 
G Sodium/potassium-transporting ATPase subunit a1 ILEYTWLEA 
H Sodium/potassium-transporting ATPase subunit a3 ILGYTWLEA 
I Voltage-dependent calcium channel subunit a2/d1 NRTYTWTPV 
J Vdac3 voltage gated anion channel PTIYGWAVL 
JAA Vdac3 voltage gated anion channel PTIAGAAVL 
K Voltage-dependent anion-selective channel protein 1 ETKYRWTEY 
L Voltage-dependent anion-selective channel protein 2 ETKYKWCEY 
N1 nidogen-1 THIYQWRQT 
N1AA nidogen-1 THIAQARQT 
N4 nidogen-1 STGYCWCVD 
N3 nidogen-1 LVGFLWKSN 
N3AA nidogen-1 LVGALAKSN 
O Lysosome membrane protein 2 GLIFTWLAC 
P Putative phospholipase B-like 2 CPPFQWSKS 
R St13 Hsc70-interacting protein AQPYKWRGK 
SV2A SV2A IPHYGWSFQ 
SV2B SV2B IPHYGWGFS 
SV2C SV2C IPHYGWSFS 
ND3-1 nidogen-2 GGLFGWLFA 
ND3-2 nidogen-2 STGFCWCVD 
ND3-3 nidogen-2 KSDFCWCVD 
N2 nidogen-2 NQTWSYHID 
N2AA nidogen-2 NQTASAHID 
ND3-5 nidogen-2 KEFYHYRDS 
 
Supplementary Data Table 1.  
Components of signalling endosomes containing variants of the YEW motif. The 
sequences of the nine-residue peptides containing these motifs, which were identified in the 
proteome of HCT-positive axonal signalling endosomes, are shown on the right, whilst 
unique identifiers for each peptide are shown on the left. These peptides were tagged with 
biotin and HPLC-purified before further analyses. Peptides that showed detectable binding 
in at least one of the assays shown in Fig. 1a and Supplementary data Fig. 2 are in bold, and 
the N1 (nidogen-1) and N2 (nidogen-2) peptides are in red. 
 
Bond HCT Distance (Å) 
nidogen-1 
(N1 peptide) 
H-bond    
1 A:ASP1214[OD2] 2.81 P:THR1[OG1] 
2 A:ARG1226[NE] 3.47 P:GLN5[OE1] 
3 A:LYS1143[NZ] 2.91 P:GLN8[OE1] 
4 A:LYS1143[NZ] 3.22 P:GLN8[O] 
5 A:ASP1278[OD1] 3.08 P:GLN8[NE2] 
Polar    
6 A:ILE1224[O] Via a water molecule P:GLN5[OE1] 
7 A:LYS1213[O] Via a water molecule P:ILE3[O] 
8 A:GLY1233[ O ] 3.15 P:HIS2[ND1] 
 
Supplementary Data Table 2.  
Potential hydrogen bonds and other polar interactions between HCT (A) and the N1 
peptide from nidogen-1 (P). The predicted distance between the interacting residues is 
indicated. Distances must be considered as indicative, since they are based on a theoretical 
model. Contacts and concealed surfaces were calculated with server PISA 
(http://www.ebi.ac.uk). 
 
Bond HCT 
Distance 
(Å) 
nidogen-1 
(G2 domain) 
1 A:ASN1144[ND2] 2.64 D:HIS 575[O] 
2 A:ASN1144[ND2] 2.85 D:VAL 580[O] 
3 A:THR1146[OG1] 3.48 D:THR 582[O] 
4 A:ASN1216[ND2] 3.67 D:GLU 521[OE2] 
5 A:TYR1229[OH] 2.91 D:SER 584[OG] 
6 A:ASN1277[N] 2.63 D:THR 614[OG1] 
7 A:ASN1277[ND2] 3.83 D:THR 614[O] 
8 A:ILE1145[O] 3.85 D:THR 582[OG1] 
9 A:LYS1213[O] 3.88 D:THR 586[OG1] 
10 A:ASP1214[O] 2.82 D:ARG 610[NH1] 
11 A:GLY1215[O] 2.71 D:ARG 610[NH2] 
12 A:GLY1215[O] 3.56 D:THR 523[OG1] 
13 A:ALA1217[O] 3.06 D:ASN 530[ND2] 
14 A:TYR1229[OH] 3.74 D:THR 586[N] 
15 A:TYR1229[OH] 2.94 D:GLN 608[NE2] 
 
Supplementary Data Table 3.  
Potential hydrogen bonds between HCT (A) and the G2 domain of nidogen-1 (D). The 
predicted distance between the interacting residues of HCT (A) and the intact G2 domain of 
nidogen-1 (D) is indicated. Distances must be considered as indicative, since they are based 
on a theoretical model. Contacts and concealed surfaces were calculated as described in 
Supplementary Data Table 2. 
 
 
 
 
Supplementary Fig. 1.  
The N1 peptide binds to HCT in ELISA and immunoprecipitation assays. (A) Selected 
peptides (see Supplementary Data Table 1) were dried on 96-well plates, blocked for non–
specific binding and incubated with VSVG-tagged HCT, which was detected by ELISA at 
490 nm using Tris-buffered saline (TBS) as a control. Statistical significance was tested 
using paired t test (n=3; *, p<0.05; error bars: SD). (B) Selected biotin-tagged peptides 
containing variants of the YEW motif and their alanine mutants were bound to streptavidin 
beads and incubated with recombinant VSVG-tagged HCT. After washing, the captured 
HCT was eluted from the beads, subjected to SDS-PAGE and detected by western blotting. 
Band intensity was determined by densitometry using ImageJ. The results were normalized 
to empty beads control and analyzed using paired t test (n=3 for wild type peptides, n=2 for 
mutants; *, p<0.05; error bars: SD). 
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Supplementary Fig. 2.  
Molecular modelling of HCT-N1 peptide and HCT-nidogen-1 G2 domain interactions. 
(A) Module structure of nidogen-1 showing the position of the N1 peptide within the b-
barrel G2 domain (cyan; top). In addition to the G2 domain, nidogen-1 contains a nidogen 
domain (NIDO), six EGF-like domains (EGFs), a thyroglobulin type 1 domain (TG) and 
five low-density lipoprotein receptor (LY) domains. Crystal structure of nidogen-1 G2 
domain (cyan; bottom) with the stick model of the N1 peptide (orange; bottom, PDB ID: 
1h4u(36). (B) Model of the complex of G2 domain of human nidogen-1 (cyan) and HCT 
(orange). The G2 domain was manually superimposed to the N1 peptide, using the graphic 
program Coot (30). (C) Details of the crystal structure of HCT (orange) bound to peptide 
N1 (stick model; PDB code 1XYW(6)). The N1 peptide was built using Coot, the glutamic 
acid of the YEW sequence present in the PDB structure 1XYW(6) was replaced with a 
glutamine; the remaining residues (THI---RQT) were manually built and adjusted inside the 
crevice of the toxin. The surface concealed by the formation of the N1 peptide-HCT 
complex is 518 Å2 for the HCT domain and 592 Å2 for the N1 peptide. This site is located 
on the opposite side of the main binding domain for polysialogangliosides, which have an 
established role as clostridial neurotoxin co-receptors (18), and should not interfere with 
ganglioside binding. (D) Qualitative electrostatic potential surface of interacting regions of 
HCT (left) and the nidogen-1 G2 domain (right). Circles highlight the two interacting areas, 
which are predicted to be complementary in terms of electrostatic charges. The bottom of 
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the HCT crevice is slightly positively charged, whilst the two borders are mostly negative; 
in contrast, the central area of the interacting surface of nidogen-1 is negatively charged, 
whilst the borders are positive. 
 
 
 
Supplementary Fig. 3. 
Nidogen-2 and HCT undergo transcytosis in primary motor neurons grown in 
microfluidic chambers. (A) Primary motor neurons were plated into the somal side (CB) 
of microfluidic chambers, and both CB and axonal (AX) compartments were stained with 
anti βIII tubulin antibodies to show that motor neuron axons crossed the microgrooves. 
Scale bar, 100 µm. (B) AlexaFluor555-HA-HCT (bottom left) and an antibody against 
nidogen-2 (a nidogen-2) were added to the AX compartment of microfluidic chambers 
containing primary motor neurons and incubated for 2 h at 37˚C. This allows for uptake, 
axonal retrograde transport and transcytosis of HCT and nidogen-2 in the CB compartment. 
Cell surface staining of axonally-derived, transcytosed AlexaFluor555-HA-HCT using an 
anti-HA antibody is on the top left panel. An anti-rabbit AlexaFluor647 secondary antibody 
was used to detect the transcytosed a nidogen-2 (top, middle panel). Both surface-exposed 
HCT (in green) and nidogen-2 (in blue) are transcytosed together under these conditions 
(merge, arrows; top right panel). The somatic distribution of the total AlexaFluor555-HA-
HCT, which underwent axonal retrograde transport, is shown on the bottom left panel (in 
red). Scale bar, 5 µm. 
B
phase
Į+$ mergeĮ QLGRJHQ
CB $;
A
CB $;
6XSSOHPHQWDU\)LJXUH%HUFVHQ\L
HCT
 
 
 
Supplementary Fig. 4.  
The N1 peptide of nidogen-1 delays TeNT paralysis both in the TA muscle and in the 
phrenic nerve-hemidiaphragm preparation. (A-C) Representative isometric muscle 
force recordings obtained from the ipsilateral (ipsi; injected side) and contralateral (contra; 
non-injected internal control) tibialis anterior muscles, 24 h after administration of TeNT 
preincubated with vehicle control (DMSO) (A), or the N1AA peptide (B) or the N1 peptide 
(c). Ten fold lower scale was applied to ipsilateral and contralateral traces in (A) and (B), 
while the scales are identical for both traces in (C) (n=6 mice per group). (D) TeNT 
preincubated with vehicle (DMSO) or the N1 peptide was added to the nerve-muscle 
preparations in Krebs-Ringer solution at 37°C. Muscle twitch was induced by nerve 
stimulation and paralysis times were monitored. Data is expressed as paralysis half time 
and reported as paired observations (n=4). (E) Wild type motor neurons were incubated 
either with AlexaFluor555-HCT (shown in red; 40 nM) alone, or together with full length 
nidogen-1 (1.3 nM) for 45 min at 37 °C. Cells were washed, fixed and immunostained for 
SV2C (shown in green) and βIII tubulin (not shown). (F) Mander’s coefficient was used to 
quantify the extent of co-localization. Significance was assessed by unpaired t test (n=3, 10 
images per experiment; NS, non significant; error bar: SD). Scale bar, 10 µm. 
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Supplementary Fig. 5.  
Cross-talk between the uptake and trafficking routes of TeNT and BoNTs. At 
physiological concentrations, TeNT and BoNT enter motor neurons using trafficking 
pathways that are mutually exclusive: BoNTs are mainly internalised by the synaptic 
vesicle recycling pathway, whereas TeNT is taken up by a clathrin-dependent route linked 
to axonal retrograde transport. Specific protein receptors zed on synaptic vesicles and 
exposed during synaptic activity (e.g. SV2A-C, synaptotagmin I and II) or at specialised 
entry sites of the NMJ (nidogens), direct these neurotoxins to different intracellular 
organelles. However, high concentrations of either TeNT or BoNTs alter this equilibrium 
resulting in crosstalk between their respective entry routes (arrows). Addition of exogenous 
recombinant nidogens, which would not be expected to be fully sequestered into the 
extracellular matrix, enhances HCT binding to motor neurons and reduces the co-
localization with SV2A. This model suggests that in the presence of nidogens, HCT is 
preferentially directed towards a cellular entry route linked to axonal retrograde transport 
and transcytosis in motor neurons, which is ultimately responsible for the targeting of 
TeNT to the spinal cord and the characteristic spastic paralysis of tetanus. 
 
Supplementary Movie 1.  
Mice injected in the right triceps surae muscle with TeNT showed signs of local paralysis 
(the affected limb is extended) with no grip reflex. Pre-treatment of TeNT with vehicle 
control or the N1AA peptide had no effect on the progression of tetanic paralysis. In 
contrast, when mice were injected with TeNT pre-treated with the N1 peptide, they showed 
an overall normal posture, strong grip reflex and no gait abnormalities, demonstrating a 
blockade in TeNT-induced paralysis. 
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